Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.88 USD
+0.20 (1.71%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.88 USD
+0.20 (1.71%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum F VGM
Zacks News
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 14.29% and 72.76%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 4.62% and 3.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 8% and 10.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Compugen (CGEN) delivered earnings and revenue surprises of 20% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Stock Market News for Nov 14, 2023
by Zacks Equity Research
Wall Street closed mixed on Monday as market participants awaited the release of a key inflation data.
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
by Zacks Equity Research
Immunovant (IMVT) announces encouraging initial results from its early-stage study of IMVT-1402. The stock of the company rallies 97%.
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 5.66% and 53.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Equillium, Inc. (EQ) delivered earnings and revenue surprises of 47.37% and 6.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 2.04% and 8.97%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -6.06% and 2.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Roivant (ROIV) Up on Reports of Colitis Drug Sale to Roche
by Zacks Equity Research
Roivant's (ROIV) RVT-3101, a once-monthly subcutaneously administered anti-TL1A antibody, is being developed for ulcerative colitis and Crohn's disease
Roivant Sciences Ltd. (ROIV) Surges 8.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Company News for Jun 29, 2023
by Zacks Equity Research
Companies in The News Are: AVAV, UNF, GIS, ROIV.
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of 51.22% and 44.56%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -52.27% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Roivant Sciences Ltd. (ROIV) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -36.11% and 19.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug
by Zacks Equity Research
Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.
Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal
by Kinjel Shah
Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -2.44% and 86.73%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Roivant Sciences Ltd. (ROIV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of -11.11% and 156.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?